Sign in

IMMX on Nasdaq

Immix Biopharma, Inc.

Immix Biopharma, Inc. is an American pharmaceutical preparations company based in Los Angeles.1 Its shares trade on Nasdaq under the symbol IMMX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerIMMX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersLos Angeles, California1
  • Incorporated inDE2
  • Business address11400 West Olympic Blvd., Suite 200, Los Angeles, Ca 900642
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Update- NEXICART-2” above for information regarding trial results as of November 13, 2025.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income56789-$30.0M in 2025+6500% since 2020
-$30.0M-$20.0M-$10.0M02020: -$453.9K-$453.9K20202021: -$1.4M-$1.4M2021+198%2022: -$8.2M-$8.2M2022+508%2023: -$16.1M-$16.1M2023+96%2024: -$22.7M-$22.7M2024+40%2025: -$30.0M-$30.0M2025+32%
Net income578910-$29.4M in 2025+2461% since 2020
-$30.0M-$20.0M-$10.0M02020: -$1.1M-$1.1M20202021: -$24.4M-$24.4M2021+2024%2022: -$8.2M-$8.2M2022−66%2023: -$15.4M-$15.4M2023+87%2024: -$21.6M-$21.6M2024+40%2025: -$29.4M-$29.4M2025+36%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
General and administrative expenses$13.7M$11.4M
Research and development$16.3M$11.3M
Total operating expenses$30.0M$22.7M
Loss from operations-$30.0M-$22.7M
Interest income$555.5K$1.0M
Total other income$555.5K$1.0M
Loss before provision for income taxes-$29.4M-$21.7M
Provision for income taxes$37.7K$41.0K
Net loss-$29.4M-$21.7M
Net loss attributable to non-controlling interests$85.0K
Net loss attributable to Immix Biopharma, Inc. common stockholders-$29.4M-$21.6M
Foreign currency translation$61.2K-$135.7K
Total other comprehensive income (loss)$61.2K-$135.7K
Comprehensive loss-$29.4M-$21.7M
Loss per common share - basic-$0.89-$0.76
Loss per common share - diluted-$0.89-$0.76
Weighted average shares outstanding - basic33.0M shares28.3M shares
Weighted average shares outstanding - diluted33.0M shares28.3M shares

Compare Immix Biopharma, Inc. with another company

Corporate structure

Immix Biopharma, Inc. sits at the top of its group. 5 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Immix Biopharma, Inc.

  • Immix Biopharma, Inc. Los Angeles, California
    • Immix Biopharma Australia Pty Ltd. Subsidiary · Australia
    • Immix Biopharma Immunology, Inc. Subsidiary · Delaware, United States
    • Immix Biopharma Innova, Inc. Subsidiary · Delaware, United States
    • Nexcella, Inc. Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Immix Biopharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$2.5M9 Dec 31, 2025$1.7M9 Dec 31, 2024+44.9%
Operating-lease assets (leased space)$966.9K9 Dec 31, 2025$989.5K9 Dec 31, 2024−2.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$93.9M9 Dec 31, 2025$17.7M9 Dec 31, 2024+431.2%
Marketable securities, current$6.5M9 Dec 31, 2025

Properties, in its own words

Our executive office is located at 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064, which the Company leases on an as needed basis. We believe that our existing facilities are suitable and adequate to meet our current needs. We intend to add new facilities or expand existing facilities as we add employees, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.

In January 2024, the Company entered into a long-term operating lease agreement for manufacturing space in California under a non-cancelable financing lease that expires in December 2033. Under the terms of the lease, we expect to make total lease payments of $1.4 million through December 2033.

Item 2 of the 10-K filed Mar 25, 2026.4

Leadership

Who has led Immix Biopharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ilya M. Rachman2021–now

Chair

  1. Ilya M. Rachman2021–now

President

  1. Gabriel S. Morris2026–now

Chief financial officer

  1. Gabriel S. Morris2021–now
2025
Board members and other officers (10)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJane Buchan named May 20, 202424

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Immix Biopharma Australia Pty Ltd. Australia3
  • Immix Biopharma Immunology, Inc. Delaware3
  • Immix Biopharma Innova, Inc. Delaware3
  • Nexcella, Inc. Delaware3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Sep 30, 20268-K Other events25
  2. Sep 29, 20268-K Regulation FD disclosure; Other events26
  3. Jul 20, 20268-K Other events27
  4. May 29, 20268-K Shareholder vote28
  5. May 21, 20268-K Regulation FD disclosure; Other events29
  6. May 21, 20268-K Other events30
  7. Mar 30, 20268-K Regulation FD disclosure; Other events31
  8. Mar 25, 20268-K Entered a material agreement32
  9. Dec 8, 20258-K Regulation FD disclosure; Other events33
  10. Dec 8, 20258-K Entered a material agreement34
  11. Nov 26, 20258-K Other events35
  12. Sep 8, 20258-K Entered a material agreement; Unregistered sale of shares; Executive or director change36
  13. Dec 15, 2021New chief executive Ilya M. Rachman becomes CEO12

Calendar

Coming up

  1. Nov 6, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.24) a share, on Nov 7, 2025.37

Drug trials and FDA: coming up

  1. Dec 2026Phase 1/2 trial readout expected Phase 1/2 trial of NXC-201 CAR-T in Light Chain (AL) Amyloidosis, run by Nexcella Inc.: primary completion expected Dec 2026 (ClinicalTrials.gov NCT06097832).38

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

237 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 34 major events, 96 insider forms, 15 large holders, 1 private raises, 69 other. The latest 20:

  1. Sep 30, 20268-K EDGAR
  2. Sep 29, 2026FWP EDGAR
  3. Sep 29, 2026424B5 EDGAR
  4. Sep 29, 20268-K EDGAR
  5. Aug 14, 2026SCHEDULE 13G EDGAR
  6. Aug 13, 2026SCHEDULE 13G/A EDGAR
  7. Aug 7, 202610-Q EDGAR
  8. Jul 20, 20268-K EDGAR
  9. Jun 5, 2026SCHEDULE 13G/A EDGAR
  10. May 29, 20268-K EDGAR
  11. May 29, 20264 EDGAR
  12. May 29, 20264 EDGAR
  13. May 29, 20264 EDGAR
  14. May 29, 20264 EDGAR
  15. May 29, 20264 EDGAR
  16. May 29, 20264 EDGAR
  17. May 29, 20264 EDGAR
  18. May 29, 20264 EDGAR
  19. May 29, 20264 EDGAR
  20. May 21, 20268-K EDGAR

The 237 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

42 open-market trades by officers, directors and large owners since October 2021: 40 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 10, 2025Rachman Ilya MCEO and ChairmanBuy746$6.67$5.0KForm 4
Dec 10, 2025Morris Gabriel SCFO, PresidentBuy770$6.58$5.1KForm 4
Sep 17, 2025Rachman Ilya MCEO and ChairmanBuy2,500$2.02$5.0KForm 4
Sep 16, 2025Morris Gabriel SCFO, PresidentBuy2,600$1.97$5.1KForm 4
Jun 18, 2025Rachman Ilya MCEO and ChairmanBuy2,178$2.30$5.0KForm 4
Jun 18, 2025Morris Gabriel SCFO, PresidentBuy2,225$2.28$5.1KForm 4
Dec 23, 2024Hsu JasonDirectorBuy40,000$2.19$87.6KForm 4
Dec 20, 2024Hsu JasonDirectorBuy7,700$2.17$16.7KForm 4
Aug 22, 2024Hsu JasonDirectorBuy8,100$2.25$18.2KForm 4
Aug 21, 2024Hsu JasonDirectorBuy15,000$2.23$33.5KForm 4
Aug 16, 2024Ng CareyDirectorBuy10,000$1.86$18.6KForm 4
Jul 24, 2024Hsu JasonDirectorBuy6,000$2.15$12.9KForm 4
Jul 18, 2024Hsu JasonDirectorBuy3,200$2.07$6.6KForm 4
Jun 7, 2024Morris Gabriel SCFO, PresidentBuy2,500$2.12$5.3KForm 4
Jun 7, 2024Rachman Ilya MCEO and ChairmanBuy2,600$2.13$5.5KForm 4
Jun 4, 2024Morris Gabriel SCFO, PresidentBuy3,300$1.81$6.0KForm 4
Jun 4, 2024Rachman Ilya MCEO and ChairmanBuy3,300$1.81$6.0KForm 4
May 14, 2024Morris Gabriel SCFO, PresidentBuy4,500$2.23$10.0KForm 4
May 14, 2024Rachman Ilya MCEO and ChairmanBuy4,300$2.25$9.7KForm 4
Dec 11, 2023Hsu JasonDirectorBuy31,000$4.67$144.8KForm 4

All 42 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Gabriel Morris,$475.0K$1.4M47
2025Ilya Rachman,$475.0K$1.4M47
2024Chief Executive Officer$475.0K$1.3M47
2024Chief Financial Officer$475.0K$1.3M47

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. May 20, 2024Filed a private offering of equity24 Form D: 14 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Jupiter Topco LLC9,783,192$100.8M0.0%New
Saturn V Capital Management LP4,658,429$48.0M6.9%+964,844
Eventide Asset Management, LLC3,891,019$40.1M0.5%+1,342,000
State Street Corp2,996,935$30.9M0.0%+2,805,025
BlackRock, Inc.2,989,972$30.8M0.0%+2,521,595
Deep Track Capital, LP2,775,000$28.6M0.4%New
Vanguard Capital Management LLC2,507,122$25.8M0.0%+719,128
Opaleye Management Inc.2,345,000$24.2M2.2%New
Millennium Management LLC2,066,426$21.3M0.0%+316,226
UBS Group AG1,941,817$20.0M0.0%+1,864,985
Marshall Wace, Llp1,794,908$18.5M0.0%+153,356
Wellington Management Group Llp1,473,409$15.2M0.0%New
Great Point Partners LLC1,277,642$13.2M3.1%+927,642
Geode Capital Management, LLC1,201,097$12.4M0.0%+737,713
Velan Capital Investment Management LP1,085,000$11.2M6.9%+345,000
Bleichroeder LP1,000,000$10.3M1.8%No change
Logos Global Management LP1,000,000$10.3M0.4%−225,000
Franklin Resources Inc969,120$10.0M0.0%+54
Burkehill Global Management, LP544,118$5.6M0.2%+250,000
Ameriprise Financial Inc518,881$5.3M0.0%New
Citadel Advisors LLC506,157$5.2M0.0%+458,984
Blue Owl Capital Holdings LP437,552$4.5M0.7%−110,000
Northern Trust Corp418,051$4.3M0.0%+279,819
Balyasny Asset Management L.P.417,227$4.3M0.0%New
LGT Fund Management Co Ltd.416,594$4.3M0.2%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Immix Biopharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARImmix Biopharma, Inc.1
  • CIK0001873835
  • Employer ID (EIN)45-48693784
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address11400 West Olympic Blvd., Suite 200, Los Angeles, CA 900641
  • Mailing address10573 W. Pico Blvd., #58, Los Angeles, CA 900641
  • Phone(888) 958-10841
  • Shares outstanding71,539,314 as of Aug 3, 202610
  • Public float$35.7M as of Jun 30, 20254
  • AuditorCrowe LLP, Los Angeles, California PCAOB ID 173; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceJul 20, 20211
  • Filings243 in all: 4 (81), 8-K (33), 10-Q (14), 3 (12), 424B5 (9), CORRESP (9), DEFA14A (6), UPLOAD (6)1
    All 35 form types

    10-K (5), DEF 14A (5), EFFECT (5), FWP (5), S-8 (5), SCHEDULE 13G/A (5), ARS (4), S-1/A (4), S-3 (4), SCHEDULE 13G (4), 4/A (3), SC 13G (3), SEC STAFF LETTER (3), 10-K/A (2), DRS (2), S-1 (2), SC 13G/A (2), 10-Q/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), D (1), DRSLTR (1), RW (1), RW WD (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 25, 2026
    Quarterly report (10-Q) Aug 7, 2026
    Proxy statement (DEF 14A) Apr 6, 2026
    Latest 8-K (8-K) Sep 30, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, $0.0001 par valueIMMXNasdaq

From the cover page of the 10-K filed Mar 25, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Immix Biopharma, Inc. names in Item 1A of its 10-K filed Mar 25, 2026: 60 risks under these headings, as written.4

  • Risks Relating to Our Financial Position and Capital Needs
  • We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.
  • We need significant additional financing to fund our operations and complete the development and, if approved, the commercialization of our product candidates. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.
  • We currently have no source of revenues. We may never generate revenues or achieve profitability.
  • Our ability to use net operating losses to offset future taxable income may be subject to limitations.
  • Economic uncertainty may affect our access to capital and/or increase the costs of such capital.
  • The pausing or termination of government grants by the United States government could have a major effect on the pharmaceutical industry, and as a result, our operations and prospects.
  • A shutdown of the U.S. federal government may adversely affect our business.
  • Inadequate funding for the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies’ staffing and operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • We may not receive the remaining $1.8 million of the $8 million which we learned was granted to us by the California Institute for Regenerative Medicine.
  • Risks Relating to the Development and Regulatory Approval of Our Product Candidates
The other 50 risks
  • We have a limited number of product candidates, all which are still in early clinical or pre-clinical development. If we do not obtain regulatory approval of one or more of our product candidates, or experience significant delays in doing so, our business will be materially adversely affected.
  • Clinical trials are expensive, time consuming, difficult to design and implement, and involve uncertain outcomes. Results of previous pre-clinical studies and clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or other regulatory authorities.
  • If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, or at all, which would require us to incur additional costs and delay our receipt of any product revenue.
  • The design or our execution of clinical trials may not support regulatory approval.
  • We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being studied which could delay or prevent the start of clinical trials for our product candidates.
  • Our product candidates may have undesirable side effects that may delay or prevent marketing approval or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales; no regulatory agency has made any such determination that any of our product candidates are safe or effective for use by the general public for any indication.
  • In general, CAR-T cell therapy has historically been associated with serious toxicities.
  • We are dependent on third parties for manufacturing and marketing of our product candidates. If we are not able to secure favorable arrangements with such third parties, our business and financial condition could be harmed.
  • If a third-party contract manufacturing organization (“CMO”) upon whom we rely to formulate and manufacture our product candidates does not perform, fails to manufacture according to our specifications or fails to comply with strict regulations, our pre-clinical studies or clinical trials could be adversely affected and the development of our product candidates could be delayed or terminated or we could incur significant additional expenses.
  • In the event that we need to change our CMOs, our pre-clinical studies, clinical trials or the commercialization of our product candidates could be delayed, adversely affected or terminated, or such a change may result in significantly higher costs.
  • We may have conflicts with our future partners that could delay or prevent the development or commercialization of our product candidates.
  • We may not be able to conduct, or contract others to conduct, animal testing in the future, which could harm our research and development activities.
  • If any of our product candidates receive regulatory approval, the approved products may not achieve broad market acceptance among physicians, patients, the medical community and third-party payors, in which case revenue generated from their sales would be limited.
  • Even if we receive regulatory approval to commercialize any of the product candidates that we develop, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense.
  • If any product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
  • Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain for such product candidates.
  • If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected.
  • If we are unable to effectively adapt to changes in the healthcare industry, our business may be harmed.
  • Risks Relating to our Business and Operations
  • We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.
  • If the market opportunities for our current and potential future product candidates are smaller than we believe they are, our ability to generate product revenue may be adversely affected and our business may suffer.
  • Our products will face significant competition, and if they are unable to compete successfully, our business will suffer.
  • Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or protected health information or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
  • Use of artificial intelligence in research, development, and commercial activities presents operational, regulatory, ethical, and reputational risks that could adversely affect our business.
  • Unfavorable geopolitical and macroeconomic developments could adversely affect our business, financial condition or results of operations.
  • Any international operations we undertake may subject us to risks inherent with operations outside of the United States.
  • We may not be successful in hiring and retaining key employees, including executive officers.
  • Our employees, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
  • California’s climate-disclosure laws may impose significant compliance burdens, create operational disruptions, and divert resources critical to the advancement of our clinical programs.
  • Risks Relating to our Intellectual Property
  • It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect our product candidates, others could compete against us, which may have a material adverse effect on our business.
  • If we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our potential licensors, we could lose rights that are important to our business.
  • We may incur substantial costs as a result of litigation or other proceedings relating to patents and other intellectual property rights.
  • We may infringe on the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.
  • If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.
  • We may be subject to claims that our employees or consultants have wrongfully used or disclosed alleged trade secrets.
  • Our intellectual property may not be sufficient to protect our product candidates from competition, which may negatively affect our business.
  • We conduct certain research and development operations through our Australian wholly-owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations could suffer.
  • Breakthrough Therapy designation, Fast Track designation or RPDD by the FDA, and equivalents granted by indications, may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood that any of our product candidates will receive marketing approval in any jurisdiction.
  • Orphan Drug Designation does not translate to approval and, even if we obtain FDA approval, we may not enjoy marketing exclusivity or other expected benefits.
  • Risks Related to Owning our Common Stock
  • The price of our common stock may fluctuate substantially.
  • Our common stock is currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our stockholders to sell their securities.
  • Because certain of our stockholders control a significant number of shares of our common stock, they may have effective control over actions requiring stockholder approval.
  • We do not intend to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.
  • Our third amended and restated certificate of incorporation (“Amended and Restated Certificate of Incorporation”) and our amended and restated bylaws (the “Amended and Restated Bylaws”) and Delaware law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline.
  • General Risk Factors
  • Market and economic conditions may negatively impact our business, financial condition and share price.
  • If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume may decline.
  • Future sales and issuances of our common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall. In addition, the perception that sales of our common stock could occur, could cause our stock price to fall.
  • The number of shares of our common stock available for future issuance or sale could adversely affect the per share trading price of our common stock.
  • We are an “emerging growth company” and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our common stock less attractive to investors. In addition, as a smaller reporting company we will also have reduced disclosure requirements.
  • We may be at risk of securities class action litigation.
  • Financial reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management will be required to devote substantial time to compliance matters.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
    SEC EDGAROther events
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47